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1 These authors contributed equally.A case of leukemia escape from an HLA-speciﬁc cytotoxic T lymphocyte (CTL) response in a recipient of
bone marrow transplantation is presented. Only the expression of HLA-B51, which was a mismatched
HLA locus in the graft-versus-host direction, was down-regulated in post-transplant leukemia blasts
compared with that in pre-transplant blasts. All CTL clones, that were isolated from the recipient’s blood
when acute graft-versus-host disease developed, recognized the mismatched B⁄51:01 molecule in a pep-
tide-dependent manner. The pre-transplant leukemia blasts were lysed by CTL clones, whereas the post-
transplant leukemia blasts were not lysed by any CTL clones. The IFN-c ELISPOT assay revealed that
B⁄51:01-reactive T lymphocytes accounted for the majority of the total alloreactive T lymphocytes in
the blood just before leukemia relapse. These data suggest that immune escape of leukemia blasts from
CTL pressure toward a certain HLA molecule can lead to clinical relapse after bone marrow
transplantation.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is
curative for leukemia by virtue of the immune reaction mediated
by donor T lymphocytes, termed the graft-versus-leukemia (GVL)
effect [1]. For HSCT recipients from HLA-matched donors, the
GVL effect can be triggered by minor histocompatibility antigens
[2–4], and several studies using sequential ﬂow cytometric analy-
sis with tetramers have clearly demonstrated that minor histocom-
patibility antigen-speciﬁc T lymphocytes increase in frequency in
the recipient’s blood before and during clinical regression of leuke-
mia [5–10]. On the other hand, for HLA-mismatched HSCT recipi-
ents, extremely limited biological studies have demonstrated that
the GVL effect can be mediated by mismatched HLA-speciﬁc donor
T lymphocytes [11].
Allogeneic HSCT is a well-established immunotherapy for
leukemia, but, unfortunately, some recipients relapse after trans-
plantation. It is difﬁcult to evaluate the role of individual factors
in relapse. Nevertheless, it is reasonable to assume that the selec-
tive pressure exerted by donor T lymphocytes can lead to the
outgrowth of pre-existing leukemia variants that have lost expres-
sion of gene products such as HLA molecules. Some studies have
demonstrated loss of the mismatched HLA haplotype in theY-NC-ND license. 
Murata).leukemia blasts of HSCT recipients as a consequence of loss of het-
erozygosity in chromosome 6 [12–14]. However, the mechanisms
involved in leukemia relapse after HLA locus-mismatched HSCT
remain largely uninvestigated.
This paper presents a case of selective HLA down-regulation in
post-transplant leukemia blasts but not in pre-transplant blasts of
a recipient who received bone marrow transplantation from an
HLA one locus-mismatched donor. All cytotoxic T lymphocyte
(CTL) clones that were isolated from the recipient’s blood during
acute graft-versus-host disease (GVHD) demonstrated cytotoxicity
speciﬁc for the mismatched HLA-B molecule, lysed pre-transplant
blasts but not post-transplant blasts, and persisted in the patient’s
blood until leukemia relapse. These results suggest that immune
escape of leukemia blasts from CTL pressure toward a certain
HLA allele can lead to clinical relapse.
2. Patient, materials and methods
2.1. Patient
A 24-year-old man with primary refractory T lymphoblastic
leukemia/lymphoma received allogeneic bone marrow transplan-
tation without ex vivo T lymphocyte depletion from his mother.
Because the patient had neither a sibling nor an HLA-matched
unrelated donor, his mother was chosen as an alternative
donor. PCR sequencing-based typing for HLA alleles of the
patient and mother revealed one HLA-B allele mismatch in
Table 1
HLA types of the patient and donor.
A B C DRB1 DQB1 DPB1
Patient 1101/2402 5401/5101 0102/ 0901/ 0303/ 0501/
Donor 1101/2402 5401/5201 0102/1202 0901/1502 0303/0601 0501/
The mismatched HLA allele in the graft-versus-host direction is underlined.
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consisted of 180 mg/m2 melphalan and 12 Gy total body irradia-
tion. GVHD prophylaxis consisted of 0.03 mg/kg tacrolimus and
short-term methotrexate. Neutrophil engraftment (neutrophil
count P0.5  109/l) was achieved 14 days after transplantation
with full donor-type chimera. The patient developed severe acute
GVHD involving the skin, gut, and liver on day 46 (maximum stage:
skin 3, gut 2, and liver 1; maximum grade: III on day 53), evaluated
according to previously published criteria [15]. Acute GVHD was
temporarily controlled by additional immunosuppressants, but it
was incurable and transitioned to chronic GVHD. On day 261, the
patient relapsed with ascites, a hydrocele, and a subpapillary tu-
mor. Leukemia blasts in the ascites ﬂuid were conﬁrmed by cyto-
logical examination. Immunosuppressant therapy was required
to control GVHD until his death on day 279.
2.2. Cell culture
CTL clones were isolated from a blood sample as described pre-
viously [16]. Brieﬂy, peripheral blood mononuclear cells (PBMCs)
obtained from the recipient on day 56, when severe acute GVHD
developed, were stimulated in vitro with aliquots of c-irradiated
PBMCs that had been obtained from the recipient pre-transplant
and cryopreserved. After three weekly stimulations, the CTL clones
were isolated from the polyclonal T lymphocyte culture by limiting
dilution. The CTLs were expanded by stimulation every 14 days
with 30 ng/ml OKT3 monoclonal antibody (Janssen Pharmaceuti-
cal), using unrelated allogeneic c-irradiated (25 Gy) PBMCs and
c-irradiated (75 Gy) EB virus-transformed lymphoblastoid cells
(B-LCL) as feeder cells. The culture medium consisted of RPMI-
1640-HEPES (Sigma–Aldrich) containing 10% pooled, heat-inacti-
vated human serum, and recombinant human IL-2 (R&D Systems).
The T lymphocytes were used in assays 14 days after stimulation or
1 day after thawing of a frozen aliquot. All samples were collected
after written informed consent had been obtained. B-LCLs were
maintained in RPMI-1640-HEPES with 10% FBS. COS cells were
maintained in DMEM (Sigma–Aldrich) with 10% FBS.
2.3. Flow cytometric analysis
Leukemia blasts were incubated at 37 C for 30 min with anti-
HLA-A24/A23 (One lambda), anti-HLA-A11/A1/A26 (One lambda),
and anti-HLA-B51/B52/B49/B56 (One lambda) antibodies to de-
tect A24, A11, and B51, respectively, of patient cells followed
by incubation at 37 C for 15 min with ﬂuorescein isothiocya-
nate-conjugated antimouse IgM (Beckman Coulter). To detect
HLA-DR9 of patient cells, leukemia blasts were incubated at
37 C for 30 min with ﬂuorescein isothiocyanate-conjugated
anti-HLA-DR antibody (BD Pharmingen). Antibody to detect
HLA-B54 without cross-reaction to B51 was not available. After
washing, the cells were analyzed by a BD FACSAria (BD Biosci-
ences). Leukemia blasts were sorted by BD FACSAria with anti-
CD7 (BD Biosciences) and anti-CD10 (eBiosciences) antibodies
from pre-transplant bone marrow and post-transplant ascites
ﬂuid samples. The purities of pre-transplant and post-transplant
blasts were 62% and 99%, respectively. CTL clones were ana-
lyzed using three-color ﬂow cytometry for expression of CD3,CD4, and CD8 using phycoerythrin-cyanin 5.1-conjugated anti-
CD3 (Beckman Coulter), phycoerythrin-conjugated anti-CD4 (BD
Biosciences), and ﬂuorescein isothiocyanate-conjugated anti-CD8
(BD Biosciences) antibodies.2.4. Chromium release assay
Leukemia blasts and B-LCLs were used as target cells in a cyto-
toxicity assay. Leukemia blasts and B-LCLs were labeled for 2 h
with 51Cr. After washing, the cells were dispensed at
2  103 cells/well into triplicate cultures in 96-well plates and
incubated for 4 h at 37 C with CTL clones at various E:T ratios. Per-
cent-speciﬁc lysis was calculated as [(experimental cpm – sponta-
neous cpm)/(maximum cpm – spontaneous cpm)] 100.2.5. Determination of T cell receptor (TCR)-Vb gene usage and
nucleotide sequences
TCR Vb usage was assessed by RT-PCR using primers covering
the entire families of functional TCR Vb chains [17–19]. Brieﬂy, to-
tal RNA was extracted from individual CTL clones, and cDNA was
synthesized using SuperScript III RT (Invitrogen). RT-PCR reactions
were carried out with the appropriate Vb sense primers speciﬁc for
different Vb families and a primer speciﬁc for the constant region
of TCR-b. Subsequently, the complementarity determining region
3(CDR3) of each positive PCR product was sequenced with corre-
sponding antisense primer. TCR Vb gene usage was determined
by the international ImMunoGeneTics information system (IMGT)
software, IMGT/V-QUEST (http://www.imgt.org/).2.6. HLA-B cDNA constructs
Total RNA was extracted from the patient and donor B-LCLs and
converted into cDNA. Constructs containing the full-length HLA-
B⁄51:01, B⁄52:01, and B⁄54:01 cDNA were generated from the cDNA
by PCR and cloned into the pEAK10 expression vector (Edge Bio-
Systems). Two mutated HLA-B⁄51:01 cDNA constructs, in which
amino acid at position 63 or 67 was substituted with the corre-
sponding amino acid in B⁄52:01, and two more mutated HLA-
B⁄51:01 cDNA constructs, in which the amino acid at position
194 or 199 was substituted with the corresponding amino acid
in B⁄44:03, were produced using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene).2.7. Transfection of B-LCLs and COS cells with HLA cDNA
B-LCL (5  106) were transfected by electroporation (200 V,
500 lFD) in 200 ll of potassium-PBS with the 15 lg of pEAK10
plasmid encoding HLA-B⁄51:01 cDNA and selected with puromycin
(Edge BioSystems), beginning 48 h after transfection. Three days
after selection, they were used as targets in a chromium release as-
say. COS cells (5  103) were plated in individual wells of 96-well
ﬂat-bottom plates and transfected with 100 ng of the pEAK10
plasmid encoding HLA-B⁄51:01, HLA-B⁄52:01, HLA-B⁄54:01, or
mutated HLA-B⁄51:01 cDNA using the FuGENE 6 Transfection
Reagent (Roche).
Fig. 1. HLA expression on leukemia blasts. Pre-transplant and post-transplant
leukemia blasts were stained with anti-HLA-A24/A23, anti-HLA-A11/A1/A26, anti-
HLA-B51/B52/B49/B56, and anti-HLA-pan DR antibodies to detect A⁄24:02, A⁄11:01,
B⁄51:01, and DRB1⁄09:01, respectively. Data are representative of four experiments.
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COS transfectants (5  103) were cocultured with CTL clones
(2  104) in individual wells of 96-well ﬂat-bottom plates for
24 h at 37 C, and IFN-c production was measured in the superna-
tant using ELISA (Endogen).
2.9. Enzyme-linked immunospot (ELISPOT) assay
T lymphocytes were isolated from recipient’s PBMCs by nega-
tive depletion using the Pan T Cell Isolation Kit II (Miltenyi Biotec)
and used as responder T cells. Responder T cells at a concentration
of 2  105 per well were plated in individual wells of the 96-well
MultiScreen-IP ﬁlter plates (Millipore) coated with anti-human
interferon (IFN)-c antibody (5 lg/ml; Mabtech) and tested in trip-
licate against a total of 2  105 stimulator cells: patient B-LCL, do-
nor B-LCL, and HLA-B⁄51:01-transfected donor B-LCL. The plates
were incubated for 24 h at 37C, washed, and incubated with bio-
tinylated anti-human IFN-c antibody (1 lg/ml; Mabtech) for 2 h at
room temperature. After addition of streptavidin (Fitzgerald Indus-
tries International) to the wells, the plates were developed with a
3-amino-9-ethylcarbazol substrate kit (Vector Laboratories). Spots
were counted using a microscope, and mean numbers were calcu-
lated from triplicate wells after subtraction of the number of spots
obtained with medium alone.Fig. 2. Cytotoxicities of CTL clones against B-LCLs. B-LCLs that originated from the
recipient (gray) and the donor (black) were used as targets for CTL clones. Speciﬁc
lysis is shown as the mean and SD of triplicate cultures at an E:T ratio of 10:1.
⁄Signiﬁcant difference (p < 0.0001: Student’s t-test) in the lysis of recipient B-LCL
compared with donor B-LCL. Data are representative of three experiments.3. Results
3.1. Selective down-regulation of HLA-B locus in post-transplant
leukemia blasts
To determine whether expressions of some HLA loci in post-
transplant relapsed leukemia blasts were down-regulated or lost,
ﬂow cytometric analysis was performed for HLA-A⁄24:02,
A⁄11:01, B⁄51:01, and DR⁄09:01 using anti-HLA-A24/A23, -HLA-
A11/A1/A26, -HLA-B51/B52/B49/B56, and -pan HLA-DR antibodies,
respectively. The expression of B⁄51:01 was down-regulated in
post-transplant leukemia blasts compared with that in pre-trans-
plant blasts, whereas expressions of A⁄24:02, A⁄11:01, and
DR⁄09:01 were the same or higher in post-transplant blasts than
in pre-transplant blasts (Fig. 1). These data led us to question
whether B⁄51:01-selective pressure mediated by donor T lympho-
cytes was present in the patient post-transplant.Table 2
Clonotypes of isolated CTL clones.
CTL TCR Vb Nucleotide and deduced amino acid sequences of complementari
TK1 Vb6.5 GCC AGC AGT CCC GGG ACT AGC GGA AC
A S S P G T S G T
TK2 Vb20 AGT CAG GGG CCG GCG GTT ACC GGG GA
S Q G P A V T G E
TK3 Vb20 AGT CAG GGG CCG GCG GTT ACC GGG GA
S Q G P A V T G E
TK4 Vb19⁄1 GCC AGT ACT TGG GGT TAC CCA CAG GG
A S T W G Y P Q G
TK5 Vb19⁄1 GCC AGT ACT TGG GGT TAC CCA CAG GG
A S T W G Y P Q G
TK6 Vb12 GCC AGC AGT TTA GCT AGC GGG AGG GC
A S S L A S G R A
TK7 Vb12 GCC AGC AGT TTA GCT AGC GGG AGG GC
A S S L A S G R A
TK8 ND
TK9 Vb12 GCC AGC AGT TTA GCT AGC GGG AGG GC
A S S L A S G R A
TK10 Vb2 GCC AGC AGT GAC TCT ATC GCG GAT GA
A S S D S I A D E
ND, not detected.3.2. Isolation of alloreactive CTL clones
Ten CTL clones, termed TK1 to TK10, were isolated from the
peripheral blood of the recipient during acute GVHD. In a cytotox-
icity assay, all isolated clones lysed recipient B-LCL but failed to
lyse donor B-LCL (Fig. 2), demonstrating that all clones were
alloreactive. Flow cytometric analysis revealed that all CTL clonesty determining region 3
C TAC GAG CAG TAC TTC
Y E Q Y F
G CTG TTT TTT
L F F
G CTG TTT TTT
L F F
G CCC GGT GCG GAT ACC GGG GAG CTG TTT TTT
P G A D T G E L F F
G CCC GGT GCG GAT ACC GGG GAG CTG TTT TTT
P G A D T G E L F F
C TCC CAT GAG CAG TTC TTC
S H E Q F F
C TCC CAT GAG CAG TTC TTC
S H E Q F F
C TCC CAT GAG CAG TTC TTC
S H E Q F F
G CAG TTC TTC
Q F F
Fig. 3. Recognition of the HLA-B⁄51:01 molecule by CTLs. (A) COS cells were
transfected with a plasmid encoding B⁄51:01 cDNA, B⁄52:01 cDNA, B⁄54:01 cDNA, or
no cDNA cocultured with CTL clones, and IFN-c production was measured in the
supernatant using ELISA. Data are the means and SD of triplicate determinations.
⁄Signiﬁcant difference (p < 0.01: Student’s t-test) in the IFN-c production stimulated
by B⁄52:01 cDNA, B⁄54:01 cDNA or no cDNA compared with B⁄51:01 cDNA. Data are
representative of three experiments. (B) Recipient B-LCL (square), donor B-LCL
(circle), and donor B-LCL transfected with HLA-B⁄51:01 cDNA (triangle) were used as
targets for CTL clones. Speciﬁc lysis is shown as the mean and SD of triplicate
cultures at various E:T ratios. Signiﬁcant difference (⁄p < 0.01; ⁄⁄p < 0.05) in the lysis
of B⁄51:01-transfected donor B-LCL compared with donor B-LCL (negative control).
Data are representative of three experiments.
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sequences of the uniquely rearranged TCR Vb gene of each clone
were determined by direct DNA sequencing of the ampliﬁed PCRproducts of TCR (Table 2). The TK2 and TK3 clones had the same
nucleotide sequences in the CDR3 regions of their TCR Vb20,
suggesting that these CTLs originated from a single clone. Similarly,
TK4 and TK5, as well as TK6, TK7, and TK9, had the same nucleotide
sequences in the CDR3 regions of their TCR Vb19⁄1 and Vb12,
respectively, suggesting that each group also originated from a
single clone. Thus, the 10 isolated alloreactive CTL clones appeared
to have been derived from six independent clones.3.3. CTL clones recognized the HLA-B⁄51:01 molecule
To evaluate the possibility that isolated CTL clones recognize
the HLA-B⁄51:01 molecule, COS cells were ﬁrst transfected with
an HLA-B⁄51:01, B⁄52:01, or B⁄54:01 cDNA construct, COS trans-
fectants were cocultured with six independent CTL clones, and
then the production of IFN-c in the supernatant was measured.
The COS cells transfected with HLA-B⁄51:01 clearly stimulated
IFN-c production by six independent CTL clones, whereas neither
B⁄52:01 nor B⁄54:01 stimulated them (Fig. 3A). Then, donor B-LCL
were transfected with an HLA-B⁄51:01 cDNA construct and used
as target cells in a cytotoxicity assay. The donor B-LCL transfected
with HLA-B⁄51:01 were lysed by six CTL clones (Fig. 3B), indicating
that all clones recognized the mismatched HLA-B⁄51:01 molecule
as an alloantigen. On the other hand, these data suggest that the
CTL response toward the HLA-B⁄51:01 molecule accounted for
the majority of the recipient’s CTL alloresponse during acute
GVHD.3.4. Recognition of HLA molecules by CTL clones was peptide-
dependent
Various forms of T lymphocyte recognition of the allogeneic
major histocompatibility antigen, ranging from peptide-dependent
to peptide-independent, have been demonstrated [20]. To conﬁrm
peptide dependency in CTL recognition, examinations were fo-
cused on the difference in the amino acid sequences of the recipi-
ent B⁄51:01 and the donor B⁄52:01. They differed in two amino
acids at positions 63 and 67 (Fig. 4A), which constitute peptide
binding pockets A and/or B [21,22]. In particular, B-pocket has a
critical role in peptide binding to HLA-B⁄51:01 molecules [23],
and substitution of a single amino acid constituting peptide bind-
ing pocket can affect peptide binding [24]. Two mutated B⁄51:01
cDNA constructs, B⁄51:01-Asn63Glu and B⁄51:01-Phe67Ser, in which
individual amino acids were substituted with the corresponding
amino acid in B⁄52:01 (Fig. 4A), were generated, as well as two
more mutated B⁄51:01 cDNA constructs, B⁄51:01-Val194Ile and
B⁄51:01-Ala199Val, in which individual amino acids exist in
B⁄44:02 and other B alleles and localize outside the positions con-
stituting peptide binding pockets. COS cells were then transfected
with each wild or mutated cDNA construct and examined in the
CTL stimulation assay. IFN-c production of the TK3 clone was sig-
niﬁcantly decreased when stimulated by the B⁄51:01-Phe67Sermu-
tant in comparison with the wild-type B⁄51:01 construct (Fig. 4B).
IFN-c production of all other CTL clones, TK1, TK5, TK6, TK8, and
TK10, was signiﬁcantly decreased when stimulated by B⁄51:01-
Asn63Glu and B⁄51:01-Phe67Ser mutants in comparison with the
wild-type B⁄51:01 construct (Fig. 4B). However, both B⁄51:01-Va-
l194Ile and B⁄51:01-Ala199Val mutants stimulated all CTL clones
to the same degree as the wild-type B⁄51:01 construct. Thus, these
data suggest that recognition of the HLA-B⁄51:01 molecule by CTL
clones was peptide-dependent.
Furthermore, CTL clones should recognize certain peptides
other than leukemia antigens, presented by HLA-B⁄51:01 mole-
cules, because B⁄51:01-transfected COS cells, which are derived
from monkey kidney cells, stimulated IFN-c production of CTLs
Fig. 4. Recognition of the HLA-B⁄51:01 molecule by CTLs is peptide-dependent. (A) The amino acid sequences at position 60 to 70 of the B⁄51:01, B⁄52:01, B⁄51:01-Asn63Glu,
and B⁄51:01-Phe67Ser cDNAs are shown. Asn at position 63 was substituted with the corresponding amino acid in B⁄52:01, Glu, in the B⁄51:01-Asn63Glu mutant. Phe at
position 67 was substituted with the corresponding amino acid in B⁄52:01, Ser, in the B⁄51:01-Phe67Ser mutant. (B) COS cells were transfected with a plasmid encoding
B⁄51:01, B⁄51:01-Asn63Glu, B⁄51:01-Phe67Ser, B⁄51:01-Val194Ile, B⁄51:01-Ala199Val or B⁄52:01 cDNA construct, cocultured with CTL clones, and IFN-c production was
measured in the supernatant using ELISA. Data are the means and SD of triplicate determinations. ⁄Signiﬁcant difference (p < 0.05: Student’s t-test) in the IFN-c production
stimulated by each mutant or B⁄52:01 cDNA construct compared with the wild-type B⁄51:01 cDNA construct. Data are representative of three experiments.
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from B lymphocytes, were lysed by CTLs (Fig. 3B).3.5. Leukemia blasts escaped from immunological pressure by HLA-B-
speciﬁc CTLs
Whether the leukemia blasts escaped from the cytotoxicity of
HLA-B⁄51:01-speciﬁc CTL clones was then examined. Pre-trans-
plant and post-transplant leukemia blasts were puriﬁed by ﬂuores-
cence-activated cell sorter (purity, 62% and 99%, respectively),
and a cytotoxicity assay was performed only for the TK1 CTL clone
because of the limited number of cryopreserved blasts. Weak but
clear lysis of pre-transplant leukemia blasts by the TK1 CTL clone
was observed, whereas post-transplant leukemia blasts were notlysed (Fig. 5A). All other CTL clones (TK3, TK5, TK6, TK8, and
TK10) also did not lyse post-transplant leukemia blasts (Fig. 5B).
In addition, whether HLA-B⁄51:01-speciﬁc CTL pressure per-
sisted until leukemia relapse was examined. The IFN-c ELISPOT as-
say was performed to detect HLA-B⁄51:01-reactive CTLs in patient
blood on day 232, 1 month before clinical leukemia relapse (Fig. 6).
IFN-c-producing B⁄51:01-reactive T lymphocytes were detected at
a level nearly equal to the level of recipient B-LCL-reactive CTLs,
that is, the total CTL alloresponse.4. Discussion
The mechanism of leukemia relapse in this recipient can be
explained as follows. CTLs speciﬁc for HLA-B⁄51:01 molecule/
Fig. 5. Cytotoxicities of CTLs against leukemia blasts. (A) Puriﬁed pre-transplant
leukemia blasts (purity, 62%) (square), puriﬁed post-transplant leukemia blasts
(purity, 99%) (triangle) and donor B-LCL (circle) were used as targets for TK1 CTL
clones. Speciﬁc lysis is shown as the mean and SD of triplicate cultures at various
E:T ratios. ⁄Signiﬁcant difference (p = 0.024: Student’s t-test) in the lysis of the pre-
transplant leukemia blasts compared with the post-transplant leukemia blasts.
Data are representative of three experiments. (B) Puriﬁed post-transplant leukemia
blasts (purity, 99%) (triangle), B-LCLs from the patient (square) and donor (circle)
were used as targets for CTL clones. Speciﬁc lysis is shown as the mean and SD of
triplicate cultures at various E:T ratios. Data are representative of three experi-
ments. There was no signiﬁcant difference in the lysis of the post-transplant
leukemia blasts compared with B51-negative donor B-LCL (negative control).
Fig. 6. Detection of HLA-B⁄51:01-speciﬁc CTLs in T lymphocytes obtained from the
recipient on day 232 after transplantation. (A) Representative ELISPOT wells show
triplicate results of T lymphocytes stimulated by recipient B-LCL, donor B-LCL, and
HLA-B⁄51:01-transfected donor B-LCL. Data are representative of three experiments.
(B) The frequency of CTLs in T lymphocytes recognizing the HLA-B⁄51:01 molecule
was measured by IFN-c ELISPOT analysis. The frequency of IFN-c-producing cells is
shown against recipient B-LCL (black), donor B-LCL (white), and HLA-B⁄51:
01-transfected donor B-LCL (gray). Data are the means and SD of triplicate
determinations. ⁄p = 0.0057; ⁄⁄p = 0.0077; ⁄⁄⁄p = 0.090 (Student’s t-test). Data are
representative of three experiments.
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blood during acute GVHD, and these CTLs continued to produce
immunological pressure on leukemia blasts for at least 8 months
after transplantation, but B⁄51:01-down-regulated leukemia blasts
escaped from the pressure of B⁄51:01-speciﬁc CTLs, and then the
leukemia clinically relapsed.CTLs recognizing mismatched HLA molecules play an important
role in the immune reaction after HLA-mismatched HSCT, includ-
ing graft rejection [25–27], GVHD [28], and the GVL effect [11].
In this study, the mismatched HLA-B⁄51:01-speciﬁc CTLs could
participate both in GVHD and the GVL effect in the recipient. Ten
CTL clones were isolated from the recipient’s blood just after the
onset of grade III acute GVHD involving skin, gut, and liver, and
all clones demonstrated HLA-B⁄51:01-speciﬁc cytotoxicity in a
non-leukemia peptide-dependent manner (Fig. 3 and 4). The pa-
tient was suffering from GVHD until his death on day 279, and in
the ELISPOT assay for T lymphocytes obtained from recipient blood
on day 232, HLA-B⁄51:01-reactive T lymphocytes accounted for the
majority of alloreactive T lymphocytes (Fig. 6). Meanwhile, weak
but clear lysis of pre-transplant leukemia blasts by an HLA-
B⁄51:01-speciﬁc CTL clone was conﬁrmed (Fig. 5A), and the pri-
mary refractory T lymphoblastic leukemia/lymphoma was in
remission until day 261. These data are consistent with participa-
tion of the recipient HLA-B locus-speciﬁc CTLs both in GVHD and
the GVL effect.
Selective HLA down-regulation was seen in this patient’s post-
transplant leukemia blasts. Mechanisms that alter HLA class I
expression have been investigated and summarized as follows
[29]: (1) loss of heterozygosity in chromosome 6 and/or 15, in
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[30,31]; (2) mutations in these genes [32]; and (3) down-regula-
tion of the antigen processing machinery, including transporter
associated with antigen processing and low-molecular-weight pro-
tein genes [33]. Ten HLA-B cDNAs were cloned from puriﬁed post-
transplant leukemia blasts (purity, 99%) by RT-PCR; 5 (50%)
clones were identical to the canonical B⁄51:01 cDNA sequence,
and the others (50%) were identical to the canonical B⁄54:01 cDNA
sequence, which was another recipient B allele (data not shown).
These data suggest that down-regulation of HLA-B⁄51:01 expres-
sion in the post-transplant leukemia blasts resulted from mecha-
nisms other than loss of heterozygosity of B locus and mutation
of the B⁄51:01 gene itself, although the entire sequence of
B⁄51:01 DNA including introns has not been determined. Recently,
hypermethylation of the HLA-class I gene promoter regions has
been identiﬁed as a mechanism for transcriptional inactivation of
HLA class I genes in esophageal squamous cell carcinoma lesions
[34]. We analyzed B⁄51:01 promoter methylation by pyrosequenc-
ing of bisulﬁte-treated DNA from puriﬁed post-transplant leuke-
mia blasts and conﬁrmed no hypermethylation of the B⁄51:01
gene (data not shown). Other possible mechanisms are down-reg-
ulation of translation and post-translational modiﬁcation of the
B⁄51:01 gene, although, to the best of our knowledge, these mech-
anisms have not yet been investigated for HLA-class I genes. Fur-
ther analysis is required.
The change in expression in HLA-A⁄11:01 between pre-trans-
plant and post-transplant leukemia blasts was of similar magni-
tude, but in the opposite direction, to that observed for B⁄51:01.
Because the expression of HLA-A11 on target cells can protect
them from lysis by KIR3DL2-positive NK cells [35], the possibility
that the post-transplant blasts with high expression of HLA-A11
were resistant to NK cell-mediated cytotoxicity, resulting in leuke-
mia relapse, cannot be ruled out.
A question left unresolved is whether the present observation is
unique to this recipient or can be duplicated in additional recipi-
ents who receive HLA one locus-mismatched HSCT. However, the
present ﬁndings can explain, at least in part, the mechanism of
how leukemia relapse occurs during persistent GVHD after HSCT.
Another question is whether the present observation is unique to
T lymphoblastic leukemia/lymphoma, which is a relatively rare
subset of acute leukemia in adults. The relevance of this ﬁnding
to other leukemias, including B lymphoblastic leukemia/lym-
phoma and myeloid malignancies, should be conﬁrmed. Further ef-
forts to identify the peptides that are presented by HLA-B⁄51:01
molecules and recognized by isolated CTL clones should help to
elucidate the precise mechanisms of leukemia escape.
In conclusion, immune escape of leukemia blasts from CTL pres-
sure toward a mismatched HLA molecule/non-leukemia peptide
complex may lead to clinical leukemia relapse.Grant support
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